Latest news with #Sapale
Economic Times
5 days ago
- Business
- Economic Times
Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 months
Synopsis The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-on-month doubling of sales continues, Mounjaro's revenue could cross Rs 500 crore by March, experts estimate. Reuters A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly. US drugmaker Eli Lilly's weight-loss drug Mounjaro (tirzepatide) has crossed Rs 100 crore in sales in India in just four months of launch, making it one of the country's fastest-growing prescription brands ever by value. The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-on-month doubling of sales continues, Mounjaro's revenue could cross Rs 500 crore by March, experts estimate. After that, there could be a price erosion in the segment, as generic versions of rival GLP1 molecule semaglutide, branded as Wegovy by Danish drugmaker Novo Nordisk, are expected to flood the market. Drugs that have seen similar burgeoning growth in the past include some in the anti-diabetic category, such as Januvia (sitagliptin), Trajenta (linagliptin), Jardiance (empagliflozin), Forxiga (dapagliflozin), and Rybelsus (oral semaglutide). Wegovy, launched in early June, also saw a doubling of sales numbers with cumulative sales of the first two months at Rs 10 crore. 'Though Wegovy has a strong prescriber base because of Rybelsus (oral semaglutide), substantial promotion may be needed to reach the Mounjaro patient base for the injectable market,' said Sheetal Sapale, vice president, commercial, at PharmaTrac. Mounjaro, which was launched in late March, has so far garnered a significant patient base, selling about 160,000 units versus Wegovy's 5,000. 'As competition gets tough and branded generics come into the market, volume sales will be a major decider of who goes ahead in the race as this extent of value creation will be challenging,' Sapale said. Industry experts and doctors said the higher weight loss efficacy of 20-22% from Mounjaro compared to Wegovy's 16-18% and a lower price point make it more attractive to many patients. Wegovy is currently priced between Rs 17,345 to Rs 26,050 per pen-filled injection, which is a month's dose of four once-a-week shots. Mounjaro, which is also given on a weekly basis, is priced at Rs 14,000 to Rs 17,500 for a month's Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai, said Mounjaro has captured a major share of the market so far due to their early launch and higher weight loss efficacy. 'Diabetes patients prefer Wegovy, while non-diabetes obese patients prefer Mounjaro,' he said. Apart from chronic weight management in obesity, Mounjaro is also indicated to improve glycaemic control in adults with type-2 diabetes mellitus, which is an additional benefit. Wegovy is used for obesity treatment and selectively in reduction in risk of major adverse cardiovascular events (MACE).
Time of India
5 days ago
- Business
- Time of India
Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 months
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel US drugmaker Eli Lilly 's weight-loss drug Mounjaro (tirzepatide) has crossed Rs 100 crore in sales in India in just four months of launch, making it one of the country's fastest-growing prescription brands ever by drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker this month-on-month doubling of sales continues, Mounjaro's revenue could cross Rs 500 crore by March, experts that, there could be a price erosion in the segment, as generic versions of rival GLP1 molecule semaglutide, branded as Wegovy by Danish drugmaker Novo Nordisk, are expected to flood the that have seen similar burgeoning growth in the past include some in the anti-diabetic category, such as Januvia (sitagliptin), Trajenta (linagliptin), Jardiance (empagliflozin), Forxiga (dapagliflozin), and Rybelsus (oral semaglutide).Wegovy, launched in early June, also saw a doubling of sales numbers with cumulative sales of the first two months at Rs 10 crore.'Though Wegovy has a strong prescriber base because of Rybelsus (oral semaglutide), substantial promotion may be needed to reach the Mounjaro patient base for the injectable market,' said Sheetal Sapale, vice president, commercial, at which was launched in late March, has so far garnered a significant patient base, selling about 160,000 units versus Wegovy's 5,000.'As competition gets tough and branded generics come into the market, volume sales will be a major decider of who goes ahead in the race as this extent of value creation will be challenging,' Sapale experts and doctors said the higher weight loss efficacy of 20-22% from Mounjaro compared to Wegovy's 16-18% and a lower price point make it more attractive to many is currently priced between Rs 17,345 to Rs 26,050 per pen-filled injection, which is a month's dose of four once-a-week shots. Mounjaro, which is also given on a weekly basis, is priced at Rs 14,000 to Rs 17,500 for a month's Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai, said Mounjaro has captured a major share of the market so far due to their early launch and higher weight loss efficacy.'Diabetes patients prefer Wegovy, while non-diabetes obese patients prefer Mounjaro,' he from chronic weight management in obesity, Mounjaro is also indicated to improve glycaemic control in adults with type-2 diabetes mellitus, which is an additional benefit. Wegovy is used for obesity treatment and selectively in reduction in risk of major adverse cardiovascular events (MACE).
Time of India
11-06-2025
- Health
- Time of India
India's probiotics market doubles in 5 years, hits Rs 2,070 cr in 2025
ET Bureau Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel As Indians seek ways to improve gut health, boost immunity, and enhance digestive function, probiotics are becoming a significant ingredient in their diet. Data suggest that probiotics market clocked strong double-digit growth of 22% on a Moving Annual Total (MAT) for May, as per market research firm PharmaTrac."The probiotics market has almost doubled in the last five years," said Sheetal Sapale, vice president, commercial, PharmaTrac. The probiotics market has grown from ₹1,016 crore MAT value in 2021 to ₹2,070 crore in 2025, show pharmaceutical companies including Sun Pharma , USV, Zydus , Torrent, Mankind and Dr Reddy's are leading the market, which is mostly driven by the older brands as new launches in the last two years have garnered a revenue of approximately ₹49 crore only, data showed."The probiotics market has become a very important market as far as restoration of gut health is concerned. Ailments affecting the normal gut microbe density, especially diarrhoea, dysentery and other intestinal/stomach infections, need consumption of probiotics along with anti-infectives. In some cases, consumption of some medications also involves nausea and vomiting as side effects, wherein probiotics play an important role. The overall market has shown a 5-year value CAGR of 19% and a very strong growth of 22% in MAT May 2025," Sapale probiotic drugs account for over 90% of the market in India, it is followed by milk and milk products. Companies such as Amul and Mother Dairy are aggressively pushing probiotics, while start-ups such as The Good Bug and WellBeing Nutrition have been also attracting significant investor Mehta, MD of the Gujarat Co-operative Milk Marketing Federation which makes and sells a range of Amul dairy products, said they sell 3 million litres of probiotic buttermilk every day across India. Amul is the largest probiotic brand in the country, claimed the company."The category is growing in high double digits and has high momentum but remains very under-penetrated. India being a very large and growing market for processed foods also translates to a large addressable market for gut-related issues," said Kannan Sitaram, cofounder and partner of Fireside Ventures, an early-stage investment fund which has invested in The Good Bug and Wellbeing Nutrition."Our probiotic portfolio currently contributes around 45% to our overall fresh dairy products portfolio. The category is seeing strong growth...," said Manish Bandlish, MD, Mother month, The Good Bug raised '100 crore in a fresh funding round led by Susquehanna Asia Venture Capital, with existing investor Fireside Ventures also participating in the May, probiotics delivered a standout performance with exponential double-digit growth, signalling rising consumer preference for gut-health Rakesh Patel, consultant gastroenterology, Fortis Hospital, Kalyan, said consumption is growing rapidly in India, especially among younger people, thanks to increasing health awareness and the influence of social media and healthcare a word of caution on its rampant usage, Dr Kaushal Madan, principal director & head-gastroenterology, hepatology & endoscopy, liver transplant and biliary sciences, at Max Hospital in Saket, New Delhi, said there are several conditions and indications where probiotics have been shown to be very effective in controlling certain conditions, but "in many other illnesses, their rampant use is possibly unwarranted."
The Star
09-06-2025
- Business
- The Star
Lilly's obesity drug sales rise 60% in India amid rising demand
NEW DELHI: Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60 in India in May from April in its second full month of being on offer in the South Asian country, which has the world's third-highest number of obese people. The US drugmaker sold 126 million rupees (US$1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies. Sales of its five milligram version more than doubled to about 75 million rupees, while revenue from the 2.5 mg shot was 51 million rupees. "The patient number may have actually doubled' in May from April, Pharmarack Vice President Sheetal Sapale told Bloomberg News. The demand is gradually rising and should continue, she said. Newer patients are being introduced with the lower dose and upgraded to five-mg injections after four weeks, according to Sapale. The increase in sales reflects the need for anti-obesity solutions in the vast market in India, where Danish rival Novo Nordisk A/S is also expected to launch soon. The country's generic drugmakers are awaiting the expiration of some patents from next year to unleash a flurry of copycat treatments. On Tuesday, Biocon Ltd. received approval for Liraglutide, a generic version of Novo Nordisk's type-2 diabetes and anti-obesity drug Victoza. India has about 100 million people living with diabetes and obesity each, Eli Lilly said earlier this year. - Bloomberg
&w=3840&q=100)
Business Standard
07-06-2025
- Business
- Business Standard
Lilly's obesity drug Mounjaro's sales rise 60% in India amid rising demand
Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60 per cent in India in May from April in its second full month of being on offer in the South Asian country, which has the world's third-highest number of obese people. The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies. Sales of its 5 mg version more than doubled to about ₹7.5 crore, while revenue from the 2.5 mg shot was ₹5.1 crore. 'The patient number may have actually doubled' in May from April, Pharmarack Vice President Sheetal Sapale told Bloomberg News. The demand is gradually rising and should continue, she said. Newer patients are being introduced with the lower dose and upgraded to 5 mg injections after four weeks, according to Sapale. The increase in sales reflects the need for anti-obesity solutions in the vast market in India, where Danish rival Novo Nordisk A/S is also expected to launch soon. The country's generic drugmakers are awaiting the expiration of some patents from next year to unleash a flurry of copycat treatments. On Tuesday, Biocon Ltd. received approval for Liraglutide, a generic version of Novo Nordisk's type-2 diabetes and anti-obesity drug Victoza. India has about 100 million people living with diabetes and obesity each, Eli Lilly said earlier this year.
